Myocardial Infarction malady

MedlinePlus: Each year over a million people in the u.s. have a heart attack. about half of them die. many people have permanent heart damage or die because they don't get help immediately. it's important to know the symptoms of a heart attack and call 9-1-1 if someone is having them. those symptoms include chest discomfort - pressure, squeezing, or pain shortness of breath discomfort in the upper body - arms, shoulder, neck, back nausea, vomiting, dizziness, lightheadedness, sweating these symptoms can sometimes be different in women. what exactly is a heart attack? most heart attacks happen when a clot in the coronary artery blocks the supply of blood and oxygen to the heart. often this leads to an irregular heartbeat - called an arrhythmia - that causes a severe decrease in the pumping function of the heart. a blockage that is not treated within a few hours causes the affected heart muscle to die. nih: national heart, lung, and blood institute²³

MalaCards: Myocardial Infarction, also known as heart attack, is related to acute myocardial infarction and atherosclerosis. An important gene associated with Myocardial Infarction is MIAT (myocardial infarction associated transcript (non-protein coding)), and among its related pathways are Akt Signaling and Rho Family GTPases. The drugs timolol and verapamil and the compounds cholesterol and atp have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, whole blood and brain, and related mouse phenotypes are cardiovascular system and immune system.

Wikipedia: Myocardial infarction (MI) or acute myocardial infarction (AMI), commonly known as a heart attack,...⁴⁴ more...

OMIM: 608446

Aliases & Descriptions:

myocardial infarction 6 8 33 32 43 heart attack 6 23 myocardial infarction (disorder) 6 mi - myocardial infarction 6

myocardial infarction nos 6 myocardial infarctions 6 myocardial infarct 6 attack - heart 6

Disease types for myocardial infarction family:

myocardial infarction, susceptibility to, 1	myocardial infarction 2

Diseases related to myocardial infarction by text searches and GeneDecks gene sharing:

(show top 50)    (show all 955)

id	Related Disease	Score	Top Affiliating Genes
1	acute myocardial infarction	106.8	PIK3C2A, PIK3CG, COG2, REN, RETN, CNTF
2	atherosclerosis	81.9	PIK3C2A, PIK3CG, PI3, LRP1, LRP6, LRP8
3	hypertension	79.7	PIK3C2A, PIK3CG, LRP1, LRP6, LRP8, SH2B3
4	coronary heart disease	76.3	PIK3C2A, LRP1, COG2, RETN, KIF6, KIF2C
5	cholesterol	76.1	PIK3C2A, PIK3CG, LRP1, LRP6, LRP8, LRPAP1
6	ischemia	75.1	PIK3C2A, PIK3CG, COG2, REN, RETN, SGCB
7	prostatitis	74.6	PIK3C2A, PIK3CG, LRP1, KLF10, PDCD1, RECK
8	diabetes mellitus	74.2	PIK3C2A, PIK3CG, PI3, LRP6, SH2B3, COG2
9	rheumatoid arthritis	71.5	PIK3CG, LRP1, SH2B3, PDCD1, RECK, RETN
10	cerebritis	70.1	PIK3C2A, PIK3CG, LRP1, LRP6, LRP8, COG2
11	thrombosis	69.5	PIK3C2A, PIK3CG, LRP1, LRPAP1, COG2, RECK
12	obesity	68.9	PIK3C2A, PIK3CG, LRP1, COG2, RECK, REN
13	leukemia	68.3	PIK3C2A, PIK3CG, LRP1, LRP6, LRPAP1, SH2B3
14	fibrosis	67.9	PIK3CG, PI3, LRP1, RECK, REN, RETN
15	thyroiditis	67.3	PIK3C2A, PIK3CG, LRP1, LRPAP1, COG2, KLF10
16	neuronitis	66.8	PIK3C2A, PIK3CG, WDR12, LRP1, LRP6, LRP8
17	nephropathy	63.7	LRP1, LRPAP1, COG2, PDCD1, REN, RETN
18	hypoxia	61.9	PIK3C2A, PIK3CG, LRP1, RECK, REN, WARS
19	alzheimer's disease	59.8	PIK3CG, LRP1, LRP6, LRP8, LRPAP1, COG2
20	lupus erythematosus	59.3	PIK3C2A, PIK3CG, SH2B3, COG2, PDCD1, RECK
21	blindness	59.2	PIK3C2A, PIK3CG, COG2, REN, CNTF, VWF
22	coronary artery anomaly	58.8	PIK3C2A, LRP1, COG2, RECK, RETN, VWF
23	insulin resistance	58.7	PIK3CG, LRP1, COG2, REN, RETN, CNTF
24	cadasil	57.5	COG2, REN, RETN, CNTF, VWF, GC
25	essential hypertension	56.9	COG2, REN, RETN, VWF, SELE, SELL
26	homocysteine	56.0	PIK3C2A, COG2, REN, RETN, VWF, GCG
27	hypercholesterolemia	56.0	PIK3C2A, LRP1, COG2, RETN, VWF, PCSK9
28	multiple sclerosis	54.6	LRP1, SH2B3, PDCD1, CNR2, CNTF, KITLG
29	atrial fibrillation	53.8	PIK3C2A, RECK, REN, RETN, VWF, SELE
30	anemia	51.7	PDCD1, REN, SGCB, KITLG, VWF, GCLC
31	cerebral infarction	50.3	COG2, VWF, SELP, SERPINC1, SERPIND1, SERPINE1
32	dementia	50.3	PIK3C2A, PIK3CG, LRP1, LRP8, LRPAP1, VWF
33	hyperglycemia	50.0	PIK3C2A, PIK3CG, SH2B3, COG2, RETN, VWF
34	carcinoma	49.2	PIK3C2A, PIK3CG, PI3, LRP1, LRP6, LRPAP1
35	diabetic retinopathy	49.2	PIK3CG, KITLG, VWF, VTN, SELE, SELL
36	vasculitis	48.6	LRP1, SH2B3, PDCD1, REN, VWF, SELE
37	cerebrovascular disease	48.2	COG2, RECK, REN, RETN, VWF, SELE
38	ischemic heart disease	48.0	PIK3C2A, COG2, RETN, SELP, SETD2, SERPINE1
39	nephrotic syndrome	47.9	PIK3C2A, REN, RETN, KITLG, VWF, VTN
40	myocarditis	47.4	PIK3C2A, SGCB, SELP, SERPINC1, LPL, VASP
41	type 2 diabetes mellitus	47.2	COG2, RECK, RETN, VWF, PCSK2, GCG
42	lymphocytic leukemia	45.7	PIK3CG, RECK, KITLG, RCAN1, SELL, SELP
43	hyperhomocysteinemia	45.7	VWF, SELE, SELP, SERPINC1, SERPINE1, LPA
44	aldosteronism	45.6	PIK3CG, REN, RETN, SERPINE1, VIP, NAGLU
45	gonococcal synovitis	45.3	PIK3CG, PI3, LRP1, PDCD1, RECK, RETN
46	thrombocytopenia	44.9	PIK3C2A, RECK, KITLG, VWF, SELE, SELL
47	thrombophilia	44.3	VWF, SELE, SELP, SERPINC1, SERPINF2, SERPIND1
48	sinusitis	44.1	PI3, VWF, SELL, SELP, SERPINC1, SERPINE1
49	systemic lupus erythematosus	44.0	PDCD1, RECK, VWF, VTN, SELE, VIP
50	congestive heart failure	43.8	PIK3C2A, PIK3CG, COG2, REN, UTS2, CHRM2

Clinical features from OMIM: 608446

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 acebutolol, acebutolol hydrochloride, alteplase,recombinant, anisindione, anistreplase, atenolol, bisoprolol, bisoprolol fumarate, carvedilol, carvedilol phosphate, dalteparin, dalteparin sodium, enoxaparin, eptifibatide, esmolol, esmolol hydrochloride, heparin, heparin calcium, heparin sodium, heparin sodium (beef lung), heparin sodium (beef), heparin sodium (pork), labetalol, labetalol hydrochloride, lidocaine hydrochloride, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nitroglycerin, penbutolol, penbutolol sulfate, pindolol, propranolol, propranolol hydrochloride, reteplase,recombinant, streptokinase, sulfinpyrazone, tenecteplase, timolol, timolol hemihydrate, timolol maleate, tirofiban, tirofiban hydrochloride, urokinase, verapamil, verapamil hydrochloride

Cell-based therapeutics:

	Cardiosphere-derived cells, PMIDs: 17283259, 22336189
	Human bone marrow-derived mesenchymal stem cells , PMIDs: 19666564
	Porcine bone marrow-derived mesenchymal stem cells, PMIDs: 19666564
	Cardiomyocyte-like cells, PMIDs: 21783246
	Cardiomyocyte-like cells, PMIDs: 18941512, 17980256
	Cardiomyocyte-like cells, PMIDs: 18941512, 17980256

MalaCards organs/tissues related to myocardial infarction:

²²

id	Organ / Tissue -> Anatomical Compartment -> Cell	Relevance
1	Heart -> Myocardium -> Cardiomyocytes	Affected by disease

MGI Mouse Phenotypes related to myocardial infarction:

²⁵ (show all 26)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system phenotype	MP:0005385	31.1	PIK3CG, LRP1, PDCD1, RECK, REN, SGCB
2	immune system phenotype	MP:0005387	23.4	LRP1, REN, SGCB, CNR2, CNTF, VWF
3	muscle phenotype	MP:0005369	21.6	PIK3CG, LRP1, PDCD1, REN, SGCB, CNTF
4	hematopoietic system phenotype	MP:0005397	16.3	SH2B3, PDCD1, CNTF, RCAN1, SERPIND1, SERPINB2
5	tumorigenesis	MP:0002006	14.9	KLF10, KITLG, RCAN1, SELL, SERPINE1, BCL2
6	endocrine/exocrine gland phenotype	MP:0005379	13.9	LRPAP1, RCAN1, PCSK2, SELL, SERPINA5, VAMP8
7	other phenotype	MP:0005395	12.3	LRPAP1, SH2B3, RECK, VASP, CLU, KDR
8	cellular phenotype	MP:0005384	INF	PIK3CG, , LRP8, SH2B3, KLF10, PDCD1
9	embryogenesis phenotype	MP:0005380	INF	, RECK, GCLC, SERPINC1, SETD2, MYB
10	nervous system phenotype	MP:0003631	INF	LRP1, , LRP8, LRPAP1, PDCD1, RECK
11	behavior/neurological phenotype	MP:0005386	INF	LRP1, , LRP8, REN, CNTF, RCAN1
12	normal phenotype	MP:0002873	INF	LRP1, , LRP8, LRPAP1, REN, VTN
13	integument phenotype	MP:0010771	INF	PIK3CG, , KLF10, RECK, CNR2, KITLG
14	mortality/aging	MP:0010768	INF	PIK3C2A, LRP1, , LRP8, LRPAP1, PDCD1
15	reproductive system phenotype	MP:0005389	INF	, LRP8, LRPAP1, REN, RCAN1, PCSK2
16	growth/size phenotype	MP:0005378	INF	PIK3C2A, PIK3CG, LRP1, , LRP8, RECK
17	respiratory system phenotype	MP:0005388	INF	, SELL, SELP, LPL, BDNF, LEFTY2
18	homeostasis/metabolism phenotype	MP:0005376	INF	PIK3C2A, PIK3CG, LRP1, , LRPAP1, KLF10
19	digestive/alimentary phenotype	MP:0005381	INF	, KITLG, VWF, GCG, VEGFA, VDR
20	liver/biliary system phenotype	MP:0005370	INF	, RECK, RETN, PCSK9, GCLC, SERPINC1
21	vision/eye phenotype	MP:0005391	INF	, PDCD1, KITLG, SELE, SELP, SERPINC1
22	no phenotypic analysis	MP:0003012	INF	, VEGFA, VCAM1, RAMP2, RAMP1, LIPG
23	adipose tissue phenotype	MP:0005375	INF	PIK3C2A, LRP1, , RETN, SERPINE1, LPL
24	renal/urinary system phenotype	MP:0005367	INF	, LRPAP1, PDCD1, REN, SELP, SELPLG
25	skeleton phenotype	MP:0005390	INF	PIK3CG, LRP1, , KLF10, RECK, KITLG
26	limbs/digits/tail phenotype	MP:0005371	INF	, KLF10, RECK, KITLG, VEGFA, VDR

Articles related to myocardial infarction:

(show top 50)    (show all 3044)

id	Title	Authors	Year	Affiliating Genes
1	Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Long-term Evaluation trial. (19656211)	Borghi C.... Ambrosioni E.	2009	ACE
2	Differential impact of admission C-reactive protein levels on 28-day mortality risk in patients with ST-elevation versus non-ST-elevation myocardial infarction (from the Monitoring Trends and Determinants on Cardiovascular Diseases [MONICA]/Cooperative Health Research in the Region of Augsburg [KORA] Augsburg Myocardial Infarction Registry). (18940277)	Kuch B.... Meisinger C.	2008	CRP
3	Facilitated PCI by combination fibrinolysis or upstream tirofiban in acute ST-segment elevation myocardial infarction: results of the Alteplase and Tirofiban in Acute Myocardial Infarction (ATAMI) trial. (18055037)	Peters S.... Koehler B.	2008	PLAT
4	Plasma N-terminal B-Type natriuretic peptide as an in dicator of long-term survival after acute myocardial infarction: comparison wit h plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. (18466800)	Khan S.Q.... Ng L.L.	2008	LAMP3
5	Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. (17418290)	Khan S.Q.... Ng L.L.	2007	ADM
6	C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. (17420344)	Khan S.Q.... Ng L.L.	2007	AVP, LAMP3
7	Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. (17892995)	Greenbaum A.B.... Weaver W.D.	2007	PLAT, SERPINC1
8	C-terminal pro-endothelin-1 offers additional prognostic information in patients after acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study. (17893002)	Khan S.Q.... Ng L.L.	2007	EDN1
9	Genetic polymorphisms of platelet glycoprotein Ia and the risk for premature myocardial infarction: effects on the release of sCD40L during the acute phase of premature myocardial infarction. (16697311)	Antoniades C.... Stefanadis C.	2006	ITGA2
10	The association between homocysteine and myocardial infarction is independent of age, sex, blood pressure, cholesterol, smoking and markers of inflammation: the Glasgow Myocardial Infarction Study. (16607071)	Woodward M.... Lowe G.D.	2006	IL6
11	A rare cause of myocardial infarction: acute inferoposterior myocardial infarction after successful intravenous thrombolytic treatment of mechanical mitral prosthetic valve thrombosis. (16175440)	Altinbas A.... Altinbas E.	2005	PLAT
12	Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). (15846258)	Antman E.M.... Braunwald E.	2005	SERPINC1
13	PON1 polymorphism, diabetes mellitus, obesity, and risk of myocardial infarction: Modifying effect of diabetes mellitus and obesity on the association between PON1 polymorphism and myocardial infarction. (15654230)	Li J.... Xu X.	2005	PON1
14	Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. (15699251)	Valgimigli M.... Ferrari R.	2005	IL1RAPL2
15	Differential expression of cardiac biomarkers by gend er in patients with unstable angina/non-ST-elevation myocardial infarction: a T ACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. (14769678)	Wiviott S.D.... Braunwald E.	2004	NPPB
16	Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by ANP (J-WIND-ANP). (14745141)	Asakura M.... Kitakaze M.	2004	NPPA
17	Combined fibrinolysis using reduced-dose alteplase pl us abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia -Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study. (15274152)	Wong A.... Lim Y.L.	2004	PLAT
18	Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. (12514658)	Borghi C.... Ambrosioni E.	2003	ACE
19	Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. (11773918)		2002	PLAT
20	Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. (12241832)	Dickstein K.... Kjekshus J.	2002	ACE
21	The effect of carvedilol in patients with impaired le ft ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials? (12167391)	Otterstad J.E.... Ford I.	2002	ACE
22	Plasma concentrations of fibrinolytic factors in the subacute phase of myocardial infarction predict recurrent myocardial infarction or sudden cardiac death. (12208595)	Soeki T.... Fukuda N.	2002	PLAT, SERPINE1
23	Eptifibatide and low-dose tissue plasminogen activato r in acute myocardial infarction: the integrilin and low-dose thrombolysis in a cute myocardial infarction (INTRO AMI) trial. (11823073)	Brener S.J.... Topol E.J.	2002	PLAT
24	Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. (11940541)	Antman E.M.... Van de Werf F.	2002	SERPINC1
25	Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy. (11431653)	Srinivas V.S.... Mueller H.S.	2001	MB
26	The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. (11704395)	Zeymer U.... Neuhaus K.L.	2001	SLC9A1
27	Dyslipidemia-related risk factors for myocardial infarction and polymorphism of ApoE gene among myocardial infarction patients and their siblings (11798896)	Bai X.... Wang B.	2001	APOE
28	Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. (10933737)	SchAPmig A.... Schwaiger M.	2000	PLAT
29	High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. (10851205)	Coulter S.A.... Kleiman N.S.	2000	PLAT, SELP
30	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. (10362188)	Jang I.K.... Schwarz R.P.	1999	PLAT
31	Early use of ACE inhibitors in the treatment of acute myocardial infarction in the United States: experience from the National Registry of Myocardial Infarction 2. National Registry of Myocardial Infarction 2 participants. (10569326)	Michaels A.D.... Barron H.V.	1999	ACE
32	Reperfusion therapy in patients with acute myocardial infarction and prior coronary artery bypass graft surgery (National Registry o f Myocardial Infarction-2). (10614792)	Peterson L.R.... Tiefenbrunn A.J.	1999	PLAT
33	Comparison of double bolus urokinase versus front-loaded alteplase regimen for acute myocardial infarction. Thrombolysis in Myocardial Infarction in Korea (TIMIKO) study group. (9761098)	Park S.J.	1998	PLAT
34	Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. (9786806)	Gurwitz J.H.... Rogers W.J.	1998	PLAT
35	Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). (9581714)	Tiefenbrunn A.J.... Rogers W.J.	1998	PLAT
36	Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction--the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. (9843166)	Scarabin P.Y.... Juhan-Vague I.	1998	SERPINE1
37	TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. (9860780)	Cannon C.P.... Braunwald E.	1998	PLAT
38	Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. (9631869)		1998	ACE
39	Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. (9169397)	Malmberg K.	1997	INS
40	Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction. (9070549)	BAor F.W.... von Fisenne M.J.	1997	PLAT
41	Myocardial infarction--symptoms and procedures. Longitudinal observation of a population of 280,000 women and men--Project POL-MONICA in Krakow. VI: Enzymatic diagnosis and myocardial infarction (9163005)	Pajak A.... Pikon J.	1996	PIK3C2A
42	Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. (8790025)	Antman E.M.	1996	SERPINC1
43	The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. (7990904)	Ambrosioni E.... Magnani B.	1995	ACE
44	Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. (7923644)	Antman E.M.	1994	SERPINC1
45	Use of a standardized heparin nomogram to achieve the rapeutic anticoagulation after thrombolytic therapy in myocardial infarction. T IMI 4 investigators. Thrombolysis in Myocardial Infarction. (8018004)	Flaker G.C.... Cannon C.P.	1994	F3
46	Experiences with ACE inhibitors early after acute myocardial infarction. Rationale and design of the German Multicenter Study on the Effects of Captopril on Cardiopulmonary Exercise parameters post myocardial infarction (ECCE). (8125422)	Kleber F.X.... Winter U.J.	1993	ACE
47	A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. (8433725)	Grines C.L.... Timmis G.C.	1993	PLAT
48	Clinical outcome of acute myocardial infarction in patients on treatment with beta-blockers or calcium antagonists. A study of 7,922 hospitalized first myocardial infarctions. (1360331)	Hansen O.... Gullberg B.	1992	ABCB7
49	Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. (1906692)	Bovill E.G.... Lambrew C.T.	1991	F3
50	Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group. (1902405)	Califf R.M.... Harrelson-Woodlief L.	1991	PLAT

Genes related to myocardial infarction according to GeneCards:

(show top 50)    (show all 669)

id	Symbol	Description	Score	GeneCards Section Context
1	MIAT	myocardial infarction associated transcript (non-protein coding)	11.1	Transcripts, Publications, Summaries, Orthologs (show all 5 sections) Aliases & Descriptions
2	OLR1	oxidized low density lipoprotein (lectin-like) receptor 1	11.1	Publications, Summaries
3	MCI2	Myocardial infarction, susceptiblity to, 2	11.1	Aliases & Descriptions
4	LGALS2	lectin, galactoside-binding, soluble, 2	11.1	Publications, Summaries
5	LTA	lymphotoxin alpha (TNF superfamily, member 1)	11.1	Publications, Summaries
6	GCLC	glutamate-cysteine ligase, catalytic subunit	11.1	Summaries, Publications
7	GJA4	gap junction protein, alpha 4, 37kDa	11.1	Publications, Summaries
8	PROCR	protein C receptor, endothelial	11.1	Publications, Summaries
9	CKM	creatine kinase, muscle	11.1	Summaries, Publications
10	PTGIS	prostaglandin I2 (prostacyclin) synthase	11.1	Summaries, Publications
11	MEF2A	myocyte enhancer factor 2A	11.1	Publications, Summaries
12	CIITA	class II, major histocompatibility complex, transactivator	11.1	Publications, Summaries
13	PALLD	palladin, cytoskeletal associated protein	11.1	Publications, Summaries
14	PCSK2	proprotein convertase subtilisin/kexin type 2	11.1	Publications, Summaries
15	ACE	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	11.0	Publications
16	PLAT	plasminogen activator, tissue	11.0	Publications
17	NPPB	natriuretic peptide B	11.0	Publications
18	PIK3C2A	phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha	11.0	Publications
19	NPPA	natriuretic peptide A	11.0	Publications
20	THBD	thrombomodulin	11.0	Publications, Functions
21	APOB	apolipoprotein B (including Ag(x) antigen)	11.0	Publications
22	CHKB	choline kinase beta	11.0	Publications
23	APOE	apolipoprotein E	11.0	Publications
24	MB	myoglobin	11.0	Publications
25	FABP3	fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	11.0	Publications
26	CA3	carbonic anhydrase III, muscle specific	11.0	Publications
27	MYL4	myosin, light chain 4, alkali; atrial, embryonic	11.0	Publications
28	SAA4	serum amyloid A4, constitutive	11.0	Publications
29	MYL3	myosin, light chain 3, alkali; ventricular, skeletal, slow	11.0	Publications
30	PTX3	pentraxin 3, long	11.0	Publications
31	FGA	fibrinogen alpha chain	11.0	Publications
32	FABP12	fatty acid binding protein 12	11.0	Publications
33	SERPINE1	serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1	11.0	Publications
34	CTF1	cardiotrophin 1	11.0	Publications
35	CKB	creatine kinase, brain	11.0	Publications
36	AHSP	alpha hemoglobin stabilizing protein	11.0	Publications
37	TNNT2	troponin T type 2 (cardiac)	11.0	Publications
38	TNNI3	troponin I type 3 (cardiac)	11.0	Publications
39	F7	coagulation factor VII (serum prothrombin conversion accelerator)	11.0	Publications
40	GCLM	glutamate-cysteine ligase, modifier subunit	11.0	Publications
41	F3	coagulation factor III (thromboplastin, tissue factor)	11.0	Publications
42	HYOU1	hypoxia up-regulated 1	11.0	Publications
43	HRG	histidine-rich glycoprotein	11.0	Publications
44	ADM	adrenomedullin	11.0	Publications
45	IGES	immunoglobulin E concentration, serum	11.0	Publications
46	SERPINC1	serpin peptidase inhibitor, clade C (antithrombin), member 1	11.0	Publications
47	CRP	C-reactive protein, pentraxin-related	11.0	Publications
48	SELP	selectin P (granule membrane protein 140kDa, antigen CD62)	11.0	Publications
49	SOD3	superoxide dismutase 3, extracellular	11.0	Publications
50	SULT1A3	sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3	11.0	Publications

Pathways related to myocardial infarction according to GeneDecks:

(show top 50)    (show all 120)

id	Pathway	Score	Top Affiliating Genes
1	Akt Signaling36	15.3	PIK3CG, UTS2, CD2, ITGA2, ITGA2B, ITGAL
2	Rho Family GTPases36	14.9	KITLG, BMP6, UTS2, BDNF, KDR, BCL2
3	Cytokine-cytokine receptor interaction20	14.8	CNTF, KITLG, VEGFA, KDR, LEP, CD40LG
4	PAK Pathway36	13.8	KITLG, BMP6, UTS2, BDNF, KDR, BCL2
5	ILK Signaling36	13.7	KITLG, UTS2, BDNF, KDR, LAMA3, LAMA4
6	Malaria20	13.6	LRP1, SELE, SELP, VCAM1, CD36, CD40LG
7	Antioxidant Action of Vitamin-C36	13.5	KITLG, BMP6, UTS2, BDNF, KDR, BCL2
8	Tec Kinases Signaling36	13.4	KITLG, BMP6, UTS2, BDNF, BCL2, BAX
9	Rheumatoid arthritis20	13.4	VEGFA, ATP6V0A4, ITGAL, ITGB2, MMP1, MMP3
10	PPAR Pathway36	13.3	KITLG, UTS2, ITGA2, ITGA2B, ITGA3, ITGA4
11	PTEN Pathway36	13.3	KITLG, UTS2, BDNF, KDR, LAMA3, LAMA4
12	Hematopoietic cell lineage20	13.3	KITLG, CD2, CD36, CD14, CD59, CD34
13	Metalloproteases in connective tissue degradation10	13.2	LRP1, CMA1, LAMA3, MMP1, MMP10, MMP13
14	JAK-STAT Pathway36	13.2	KITLG, BMP6, UTS2, BDNF, KDR, BCL2
15	Rac1 Pathway36	13.0	KITLG, BMP6, UTS2, BDNF, KDR, ITGA2
16	Activation of PKA through GPCR36	12.9	KITLG, GCG, VASP, BMP6, UTS2, BDNF
17	Ras Pathway36	12.9	UTS2, KDR, ITGA2, ITGA2B, ITGA3, ITGA4
18	NF-KappaB (p50-p65) Pathway36	12.9	KITLG, BMP6, UTS2, BDNF, KDR, FLT1
19	Activation of cAMP-Dependent PKA36	12.9	KITLG, GCG, VASP, BMP6, UTS2, BDNF
20	Glioma Invasiveness36	12.8	KITLG, VTN, BMP6, UTS2, BDNF, ITGA2B
21	MAPK Family Pathway36	12.7	KITLG, BMP6, UTS2, BDNF, KDR, BCL2
22	Pertussis20	12.7	SERPING1, CD14, ITGAM, ITGB1, ITGB2, IL10
23	Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics34	12.6	REN, CMA1, BDKRB1, BDKRB2, MME, MAPK1
24	ECM-receptor interaction20	12.6	VWF, VTN, LAMA3, LAMA4, CD36, ITGA2
25	MAPK Signaling36	12.6	KITLG, BMP6, UTS2, BDNF, KDR, BCL2
26	Chagas disease (American trypanosomiasis)20	12.5	PIK3CG, SERPINE1, BDKRB2, IL10, IL12B, IL1B
27	Phospholipase-C Pathway36	12.5	KITLG, BMP6, UTS2, BDNF, KDR, LAMA3
28	JNK Pathway36	12.4	KITLG, BMP6, UTS2, KDR, BCL2, BAX
29	all-trans-Retinoic Acid Signaling in Brain36	12.4	BMP6, BCL2, BAX, CD2, IL10, IL12B
30	STAT3 Pathway36	12.3	BMP6, BCL2, BAX, JAK2, CDKN1A, CD2
31	Extrinsic Prothrombin Activation Pathway36	12.2	SERPINC1, FGA, FGB, FGG, F7, F5
32	Influenza A20	12.2	PIK3CG, CIITA, JAK2, IL12B, IL18, IL1A
33	Leishmaniasis20	12.2	JAK2, ITGA4, ITGAM, ITGB1, ITGB2, FCGR2A
34	PEDF Induced Signaling36	12.2	BMP6, BDNF, BCL2, BAX, CD2, IL10
35	TGF-Beta Pathway36	12.2	KITLG, BMP6, UTS2, BDNF, KDR, BCL2
36	Selected targets of HNF110	12.2	SERPINA1, LPA, UCP2, INS, APOA1, APOA2
37	Renin-Angiotensin Pathway36	12.2	REN, KITLG, VCAM1, BMP6, UTS2, BDNF
38	RAR-Gamma-RXR-Alpha Degradation36	12.1	CD2, ANGPT1, MAPK14, CCL11, CCL3, CCL5
39	Signaling Involved in Cardiac Hypertrophy36	12.0	JAK2, ITGA2, ITGA2B, ITGA3, ITGA4, ITGAL
40	Toxoplasmosis20	11.9	PIK3CG, BCL2, CIITA, LDLR, LAMA3, LAMA4
41	Endothelin-1 Signaling Pathway36	11.9	BMP6, CD2, FLT1, INSR, IL10, IL12B
42	Actin-Based Motility by Rho Family GTPases36	11.9	UTS2, BDNF, ITGA2B, ITGA4, ITGAL, ITGAM
43	Regulation of eIF4 and p70S6K36	11.8	BAX, CD2, ITGA2, ITGA2B, ITGA3, ITGA4
44	Selected targets of GCR-alpha10	11.7	KITLG, LEP, CHAT, UCP3, CDKN1A, INS
45	ACE Inhibitor Pathway, Pharmacodynamics34	11.6	CMA1, BDKRB1, BDKRB2, MME, MAS1, NR3C2
46	Amoebiasis20	11.3	SERPINB2, LAMA3, LAMA4, CD14, ITGAM, ITGB2
47	Glucocorticoid Receptor Signaling36	10.7	BMP6, BCL2, BAX, CDKN1A, CD2, IL10
48	African trypanosomiasis20	10.7	SELE, VCAM1, LAMA4, IL10, IL12B, IL18
49	PGC1Alpha Pathway36	10.2	BMP6, BCL2, BAX, CD2, INSR, MEF2A
50	Pathways in cancer20	10.1	PIK3CG, VEGFA, BCL2, BAX, LAMA4, JUP

Compounds related to myocardial infarction according to GeneDecks:

(show top 50)    (show all 562)

id	Compound	Score	Top Affiliating Genes
1	cholesterol32 9 18 9	33.1	PIK3C2A, LRP1, LRP8, LRPAP1, COG2, RECK
2	atp32	21.0	PIK3C2A, RECK, SGCB, WARS, KIF2C, VTN
3	indomethacin32 9 9	20.9	REN, GCG, SELL, VIP, LPL, VASP
4	glutamine32	18.3	PIK3CG, VWF, VTN, GCG, SERPINF2, VIP
5	homocysteine32 18	19.3	PIK3C2A, COG2, RETN, VWF, SELE, SELP
6	thymidine32 18	19.0	CNR2, CNTF, KITLG, SERPINA1, VIP, NAGLU
7	arachidonic acid32 9 18 9	20.2	RECK, KITLG, VWF, SELP, SERPINA1, LPL
8	ethanol32 34 9 18 9	20.7	KITLG, GCLC, SERPINA1, LPA, BPI, LIPC
9	polysaccharide32	16.6	RECK, KITLG, VTN, SELE, SELL, SELP
10	glucose32	15.0	CNTF, PCSK2, GCG, SETD2, VCAN, KCNJ11
11	progesterone32 42 9 18 9	18.9	CNTF, SETD2, SERPINB2, SERPINA3, BSG, MYB
12	formaldehyde32 18	15.8	VWF, SELE, SELL, SELP, BLZF1, CHAT
13	cyclic amp32 18	15.8	SGCB, CNR2, CNTF, PCSK2, GCG, SETD2
14	dextran sulfate32	14.6	VTN, SELE, SELL, SELP, SERPINC1, LPL
15	pd 98,05932	14.4	PIK3CG, RECK, CNTF, KITLG, VTN, GCG
16	fmlp32	14.2	PIK3CG, GC, SELL, SELP, SELPLG, SERPINA3
17	gemfibrozil32 9 9	16.1	PIK3C2A, COG2, LPA, LPL, LIPC, CHKA
18	4-hydroxynonenal32 18	15.1	GCLC, GCLM, MYB, CHKA, CHAT, UCP2
19	triacylglycerol32	14.1	COG2, GCG, SERPINE1, LPL, LIPG, LIPC
20	dmso32	13.7	KITLG, SELP, BMP6, BDKRB2, CHGA, XDH
21	candesartan32 9 9	15.6	REN, SELP, SERPINE1, VEGFA, BDKRB2, MMP1
22	glycosaminoglycan32	13.5	LRP1, VTN, SERPINC1, SERPIND1, NAGLU, VCAN
23	nifedipine32 9 9	15.3	PIK3CG, REN, GCG, SELE, SERPINE1, VIP
24	gold32	13.3	PIK3C2A, RECK, KITLG, SERPINA3, NAGLU, CHGA
25	n-formylmethionyl-leucylphenylalanine32	13.3	PIK3CG, VTN, SELL, SELP, SELPLG, LCN2
26	tirofiban32 9 9	15.2	VWF, VTN, SELP, SERPINC1, P2RY12, CD40LG
27	oleic acid32 9 18 9	16.2	LRP1, GCG, GC, LPA, LPL, LIPC
28	citrate32	13.1	PIK3C2A, SELP, NAGLU, VDR, BLZF1, CHKA
29	probucol32 9 9	15.1	SELE, LPL, VCAM1, LIPC, SCARB1, LDLR
30	iloprost32 42 9 9	16.0	SELE, SELP, SERPINC1, VCAM1, F3, F2R
31	cuprophan32	13.0	VTN, SELL, SELP, SERPINF2, VCAM1, CD14
32	l-nmma32	12.9	SGCB, VIP, VCAM1, BDKRB2, KCNMA1, XDH
33	telmisartan32 9 9	14.9	COG2, REN, LEP, INS, ALB, CYP2C19
34	corticosterone32 18	13.8	GCG, VIP, BDNF, MPO, MIF, FGF2
35	epsilon aminocaproic acid32	12.6	SERPINC1, SERPINF2, SERPINE1, LPA, APOB, F9
36	chloroquine32 34 9 9	15.5	VTN, SERPINC1, BMP6, CIITA, LDLR, CD79A
37	gf 109203x32 42	13.4	PIK3CG, KITLG, VEGFA, JAK2, CDKN1A, ITGA2B
38	acetaldehyde32 18	13.4	LCAT, XDH, CETP, FN1, IL10, IL4
39	gp 13032	12.3	RECK, CNTF, VIP, BMP6, JAK2, IL13
40	lycopene32 18	13.2	LPL, VCAM1, SCARB1, LDLR, CETP, GSR
41	erythromycin32 9 9	14.1	PIK3C2A, VIP, VCAM1, MPO, CD40LG, ITGB2
42	tamoxifen32 34 9 9	15.0	VTN, SELE, SERPINC1, VEGFA, LPL, VDR
43	nash32	12.0	RETN, LEP, UCP2, INS, GPT, AKR1A1
44	tarc32	12.0	CKLF, ITGA4, IL10, IL13, IL18, IL1A
45	arsenite32 18	12.8	PIK3CG, SETD2, VEGFA, VDR, BCL2, BAX
46	intralipid32	11.7	LPL, LIPC, LEP, UCP3, LCAT, CETP
47	quinine32 9 9	13.6	RECK, BDNF, KCNMA1, S100B, CFH, IL10
48	ionomycin32	11.4	SETD2, SERPINA3, KCNMA1, P2RY2, CD2, CD40
49	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide32	11.2	BCL2, BAX, S100B, CD40, MMP2, MMP9
50	sulforaphane32	10.7	PIK3CG, BCL2, UGT1A1, BAX, CDKN1A, GSTM1

Cellular components related to myocardial infarction according to GeneDecks:

(show all 13)

id	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:005576	30.4	LRP8, LRPAP1, RETN, KITLG, VWF, VTN
2	extracellular space	GO:005615	28.6	REN, CNTF, KITLG, VTN, PCSK9, PCSK2
3	integral to plasma membrane	GO:005887	18.2	LRP1, SGCB, CNR2, BTN2A1, SELL, SELP
4	cytosol	GO:005829	16.4	PIK3C2A, PIK3CG, SH2B3, CNTF, WARS, KIF2C
5	external side of plasma membrane	GO:009897	14.2	VWF, SELL, SELP, SERPINA5, VCAM1, KDR
6	platelet alpha granule lumen	GO:031093	14.1	VWF, SERPINF2, SERPINA1, SERPINE1, SERPING1, VEGFA
7	proteinaceous extracellular matrix	GO:005578	13.3	PI3, VWF, SERPINA1, VEGFA, VCAN, CHI3L1
8	extracellular matrix	GO:031012	13.1	VWF, VTN, SERPINE1, LPL, VCAN, CMA1
9	secretory granule	GO:030141	11.8	PCSK2, GCG, VEGFA, CHGA, AVP, MPO
10	membrane raft	GO:045121	11.3	SELE, BSG, JAK2, CD79A, CD36, CD14
11	cell surface	GO:009986	INF	, LRPAP1, PCSK9, VEGFA, LPL, VCAM1
12	caveola	GO:005901	INF	, LRP8, SELE, KCNMA1, SCARB1, SCN5A
13	plasma membrane	GO:005886	INF	PIK3C2A, PIK3CG, , LRP8, LRPAP1, PDCD1

Biological processes related to myocardial infarction according to GeneDecks:

(show top 50)    (show all 63)

id	Name	GO ID	Score	Top Affiliating Genes
1	blood coagulation	GO:007596	21.4	PIK3CG, LRP8, SH2B3, KIF2C, VWF, SELL
2	small molecule metabolic process	GO:044281	20.2	PIK3C2A, PIK3CG, GCG, GCLC, GC, GCLM
3	platelet activation	GO:030168	17.1	PIK3CG, VWF, SELP, SERPINF2, SERPINA1, SERPINE1
4	inflammatory response	GO:006954	15.9	PIK3CG, CNR2, SELE, SELP, SERPINA3, BMP6
5	signal transduction	GO:007165	15.7	LRP8, PDCD1, CNTF, KITLG, RCAN1, GCG
6	platelet degranulation	GO:002576	15.6	VWF, SELP, SERPINF2, SERPINA1, SERPINE1, SERPING1
7	proteolysis	GO:006508	15.4	LRP8, REN, PCSK2, LPA, CMA1, PAPPA
8	response to hypoxia	GO:001666	15.3	SERPINA1, VEGFA, VCAM1, UTS2, BCL2, KCNMA1
9	cell adhesion	GO:007155	14.4	KITLG, VWF, VTN, SELL, SELP, SELPLG
10	leukocyte migration	GO:050900	14.2	SELL, SELP, SELPLG, BSG, CD2, CD34
11	response to drug	GO:042493	14.1	REN, GCLM, LPL, UTS2, BDKRB2, BDNF
12	lipid metabolic process	GO:006629	14.1	LRP8, BTN2A1, LPA, LPL, LIPG, CLU
13	response to lipopolysaccharide	GO:032496	14.1	CNR2, SELE, SELP, SERPINA1, BDKRB1, KCNJ8
14	positive regulation of cell proliferation	GO:008284	13.6	CNTF, VIP, VEGFA, KDR, LEP, AVP
15	negative regulation of apoptotic process	GO:043066	13.6	PIK3CG, GCG, SERPINE1, VEGFA, CLU, BDKRB2
16	regulation of blood pressure	GO:008217	13.5	REN, RAMP2, UTS2, LEP, CHGA, CD34
17	innate immune response	GO:045087	13.4	PIK3CG, SERPING1, CLU, CLEC4A, BCL2, LCN2
18	cell surface receptor signaling pathway	GO:007166	13.3	BSG, CLEC4A, BDKRB2, CD2, CD36, CD14
19	immune response	GO:006955	13.2	CNR2, VTN, BPI, BMP6, CIITA, FCAR
20	cell-cell signaling	GO:007267	13.2	KLF10, CGB, AVP, ITGB2, AR, INHBA
21	negative regulation of cell proliferation	GO:008285	13.2	KLF10, WARS, VDR, BDKRB2, JAK2, CDKN1A
22	lipoprotein metabolic process	GO:042157	13.1	PCSK9, LPA, LPL, SCARB1, LDLR, LCAT
23	elevation of cytosolic calcium ion concentration	GO:007204	12.9	UTS2, BDKRB1, BDKRB2, SAA1, P2RY2, AVP
24	anti-apoptosis	GO:006916	12.9	GCLC, SERPINB2, BDNF, BCL2, MPO, CD40LG
25	heart development	GO:007507	12.9	VCAM1, VCAN, RAMP2, KCNJ8, ITGA4, MEF2A
26	positive regulation of angiogenesis	GO:045766	12.7	SERPINE1, VEGFA, RAMP2, UTS2, KDR, CHI3L1
27	positive regulation of protein kinase B signaling cascade	GO:051897	12.5	PIK3CG, CHI3L1, INS, INSR, ANGPT1, CCL3
28	positive regulation of cell migration	GO:030335	12.5	VEGFA, KDR, JAK2, ITGB1, MMP14, IRS1
29	acute-phase response	GO:006953	12.5	SERPINF2, SERPINA1, SERPINA3, LBP, SAA1, SAA4
30	positive regulation of peptidyl-tyrosine phosphorylation	GO:050731	12.5	LRP8, KITLG, VTN, VEGFA, JAK2, CD36
31	angiogenesis	GO:001525	12.4	PIK3CG, WARS, SETD2, SERPINE1, VEGFA, RAMP2
32	positive regulation of phosphatidylinositol 3-kinase cascade	GO:014068	12.4	CNTF, SELP, KDR, JAK2, FLT1, INS
33	fibrinolysis	GO:042730	12.4	SERPINF2, SERPINB2, SERPINE1, SERPING1, GP1BA, F2
34	reverse cholesterol transport	GO:043691	12.4	LIPG, LIPC, CLU, SCARB1, LCAT, CETP
35	xenobiotic metabolic process	GO:006805	12.4	GCLC, GCLM, UGT1A1, MTR, GSTM1, GSTP1
36	cellular response to lipopolysaccharide	GO:071222	12.3	SERPINE1, LBP, CD36, CD14, ARG1, GSTP1
37	response to glucocorticoid stimulus	GO:051384	12.3	SERPINE1, UCP3, LCAT, INSR, IL10, IL1B
38	blood coagulation, intrinsic pathway	GO:007597	12.2	VWF, SERPING1, APOH, GP5, GP1BA, F9
39	aging	GO:007568	12.1	VDR, VCAM1, SCAP, UCP3, P2RY2, GSN
40	positive regulation of nitric oxide biosynthetic process	GO:045429	12.1	JAK2, INS, INSR, IL1B, IFNG, ICAM1
41	female pregnancy	GO:007565	11.9	GC, PAPPA, BCL2, LEP, FLT1, IL1RN
42	positive regulation of inflammatory response	GO:050729	11.7	SERPINE1, JAK2, IL12B, IL18, IL1RL1, IL33
43	positive regulation of chemokine production	GO:032722	11.7	LBP, P2RY2, IL18, IL6, IL6R, TNF
44	leukocyte cell-cell adhesion	GO:007159	11.7	SELE, SELP, VCAM1, CD40LG, ITGA4, ITGAL
45	response to estrogen stimulus	GO:043627	11.5	RCAN1, SERPINE1, BCL2, APOA2, FAS, ANGPT1
46	response to organic cyclic compound	GO:014070	11.3	SELP, SERPINA1, UGT1A1, FXN, CDKN1A, CDK1
47	positive regulation of smooth muscle cell proliferation	GO:048661	11.2	SERPINF2, FLT1, IL13, IL6, IL6R, CCL5
48	response to ethanol	GO:045471	10.2	BCL2, CHAT, AVP, CDK1, MMP9, INSR
49	positive regulation of apoptotic process	GO:043065	INF	, CLU, KCNMA1, BAX, JAK2, ITGB1
50	positive regulation of transcription from RNA polymerase II promoter	GO:045944	INF	, SERPINF2, SERPINE1, VEGFA, VDR, MYB

Molecular functions related to myocardial infarction according to GeneDecks:

(show all 11)

id	Name	GO ID	Score	Top Affiliating Genes
1	heparin binding	GO:008201	14.5	FN1, FGF2, MDK, APOA5, APOB, APOE
2	heme binding	GO:020037	13.7	HMOX1, TPO, PTGIS, PTGS2, PTGS1, TBXAS1
3	cytokine activity	GO:005125	13.3	TNFSF4, SPP1, CTF1, LTA, LTB, EDN1
4	hormone activity	GO:005179	13.0	GH1, CRH, EDN1, AGT, TTR, THPO
5	eukaryotic cell surface binding	GO:043499	12.1	ADIPOQ, TGFB1, THBS1, ANXA5, MBL2, APOH
6	growth factor activity	GO:008083	12.1	THBS4, AGT, NGF, PPBP, GH1, F2
7	protease binding	GO:002020	11.6	IL1R1, F3, TNF, TNFRSF1A, ELANE, DPP4
8	enzyme binding	GO:019899	11.1	PPARG, CTNNB1, CYP2C19, CYP1A2, PTGS2, HMOX1
9	protein binding	GO:005515	INF	PECAM1, HADHA, HGF, EP300, EPO, EPOR
10	receptor binding	GO:005102	INF	, REN, GCG, SELPLG, SERPINE1, LPL
11	protein homodimerization activity	GO:042803	INF	SHBG, MYH6, MYH7, ADIPOQ, ADRB3, ADD1